摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-octylpyrimidine

中文名称
——
中文别名
——
英文名称
5-octylpyrimidine
英文别名
——
5-octylpyrimidine化学式
CAS
——
化学式
C12H20N2
mdl
——
分子量
192.304
InChiKey
BOBKHGIMWUQESJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.2
  • 重原子数:
    14
  • 可旋转键数:
    7
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    25.8
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    5-溴嘧啶1-碘辛烷吡啶三对苯甲基膦三氟乙酸 、 cobalt(II) bromide 作用下, 以 N,N-二甲基乙酰胺 为溶剂, 反应 24.0h, 以70%的产率得到5-octylpyrimidine
    参考文献:
    名称:
    杂芳基溴化物的钴催化还原烷基化:一锅法获得烷基噻吩、-呋喃、-硒吩和-吡咯
    摘要:
    报道了一种实用且方便的共催化烷基化方法,可将各种烷基链轻松引入具有电子意义的有机杂芳基化合物,包括噻吩、呋喃、硒吩和吡咯。在充分优化的反应条件下,广泛的烷基化杂芳基化合物已以中等至良好的分离产率有效制备。值得注意的是,在聚合物化学和有机材料中起决定性作用的 2- 或 3- 烷基噻吩首次通过这种使用廉价钴盐作为催化剂的还原偶联方法逐步经济地合成。这种简单的合成过程避免了传统烷基化方案所需的水分不稳定有机金属试剂(RMgX 或 RZnX)的制备。
    DOI:
    10.1002/ejoc.201500784
点击查看最新优质反应信息

文献信息

  • Cobalt-Catalyzed Reductive Alkylation of Heteroaryl Bromides: One-Pot Access to Alkylthiophenes, -furans, -selenophenes, and -pyrroles
    作者:Deng-Jhou Cai、Po-Han Lin、Ching-Yuan Liu
    DOI:10.1002/ejoc.201500784
    日期:2015.8
    A practical and convenient Co-catalyzed alkylation method for the facile introduction of various alkyl chains into organic electronically significant heteroaryl compounds, including thiophenes, furans, selenophenes, and pyrroles, is reported. Under well-optimized reaction conditions, a wide range of alkylated heteroaryl compounds have beeen efficiently prepared in moderate to good isolated yields.
    报道了一种实用且方便的共催化烷基化方法,可将各种烷基链轻松引入具有电子意义的有机杂芳基化合物,包括噻吩、呋喃、硒吩和吡咯。在充分优化的反应条件下,广泛的烷基化杂芳基化合物已以中等至良好的分离产率有效制备。值得注意的是,在聚合物化学和有机材料中起决定性作用的 2- 或 3- 烷基噻吩首次通过这种使用廉价钴盐作为催化剂的还原偶联方法逐步经济地合成。这种简单的合成过程避免了传统烷基化方案所需的水分不稳定有机金属试剂(RMgX 或 RZnX)的制备。
  • OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS
    申请人:Prosensa Technologies B.V.
    公开号:EP2870246A2
    公开(公告)日:2015-05-13
  • Oligonucleotide for the Treatment of Muscular Dystrophy Patients
    申请人:Prosensa Technologies B.V.
    公开号:US20150191725A1
    公开(公告)日:2015-07-09
    The invention relates to an oligonucleotide and to a pharmaceutical composition comprising said oligonucleotide. This oligonucleotide is able to bind to a region of a first exon from a dystrophin pre-mRNA and to a region of a second exon within the same pre-mRNA, wherein said region of said second exon has at least 50% identity with said region of said first exon, wherein said oligonucleotide is suitable for the skipping of said first and second exons of said pre-mRNA, and preferably the entire stretch of exons in between.
  • NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS
    申请人:The Scripps Research Institute
    公开号:US20170050941A1
    公开(公告)日:2017-02-23
    Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.
  • [EN] OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS<br/>[FR] OLIGONUCLÉOTIDE POUR LE TRAITEMENT DE PATIENTS ATTEINTS DE DYSTROPHIE MUSCULAIRE
    申请人:PROSENSA TECHNOLOGIES BV
    公开号:WO2014007620A2
    公开(公告)日:2014-01-09
    The invention relates to an oligonucleotide and to a pharmaceutical composition comprising said oligonucleotide. This oligonucleotide is able to bind to a region of a first exon from a dystrophin pre-mRNA and to a region of a second exon within the same pre-mRNA, wherein said region of said second exon has at least 50% identity with said region of said first exon, wherein said oligonucleotide is suitable for the skipping of said first and second exons of said pre-mRNA, and preferably the entire stretch of exons in between.
查看更多